Search

Arvinas Inc

Fechado

SetorSaúde

9.32 -0.43

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.03

Máximo

9.36

Indicadores-chave

By Trading Economics

Rendimento

227M

169M

Vendas

234M

250M

P/E

Médio do Setor

35.385

57.371

EPS

2.58

Margem de lucro

67.841

Funcionários

246

EBITDA

216M

159M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+59.83% upside

Dividendos

By Acuity

Próximos Ganhos

4 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

74M

594M

Abertura anterior

9.75

Fecho anterior

9.32

Sentimento de Notícias

By Acuity

47%

53%

145 / 340 Ranking em Healthcare

Arvinas Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 19:56 UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21 de ago. de 2026, 19:56 UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20 de ago. de 2026, 20:01 UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19 de ago. de 2026, 19:26 UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17 de ago. de 2026, 19:16 UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14 de ago. de 2026, 19:46 UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13 de ago. de 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11 de ago. de 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10 de ago. de 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7 de ago. de 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6 de ago. de 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5 de ago. de 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4 de ago. de 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 de ago. de 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 de jul. de 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 de jul. de 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 de jul. de 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 de jul. de 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 de jul. de 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 de jul. de 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Comparação entre Pares

Variação de preço

Arvinas Inc Previsão

Preço-alvo

By TipRanks

59.83% parte superior

Previsão para 12 meses

Média 14.96 USD  59.83%

Máximo 21 USD

Mínimo 8.68 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Arvinas Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

5

Comprar

6

Manter

0

Vender

Sentimento

By Acuity

145 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat